Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Carcinogenesis ; 36(6): 666-75, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25896445

ABSTRACT

Chronic inflammation is an important risk factor for lung cancer. Therefore, identification of chemopreventive agents that suppress inflammation-driven lung cancer is indispensable. We studied the efficacy of combinations of indole-3-carbinol (I3C) and silibinin (Sil), 20 µmol/g diet each, against mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and driven by lipopolysaccharide (LPS), a potent inflammatory agent and constituent of tobacco smoke. Mice treated with NNK + LPS developed 14.7±4.1 lung tumors/mouse, whereas mice treated with NNK + LPS and given combinations of I3C and Sil had 7.1±4.5 lung tumors/mouse, corresponding to a significant reduction of 52%. Moreover, the number of largest tumors (>1.0mm) was significantly reduced from 6.3±2.9 lung tumors/mouse in the control group to 1.0±1.3 and 1.6±1.8 lung tumors/mouse in mice given I3C + Sil and I3C alone, respectively. These results were paralleled by significant reductions in the level of proinflammatory and procarcinogenic proteins (pSTAT3, pIκBα and COX-2) and proteins that regulate cell proliferation (pAkt, cyclin D1, CDKs 2, 4, 6 and pRB). Further studies in premalignant bronchial cells showed that the antiproliferative effects of I3C + Sil were higher than the individual compounds and these effects were mediated by targeting cyclin D1, CDKs 2, 4 and 6 and pRB. I3C + Sil suppressed cyclin D1 by reducing its messenger RNA level and by enhancing its proteasomal degradation. Our results showed the potential lung cancer chemopreventive effects of I3C + Sil in smokers/former smokers with chronic pulmonary inflammatory conditions.


Subject(s)
Cell Transformation, Neoplastic/drug effects , Indoles/pharmacology , Inflammation/drug therapy , Lung Neoplasms/drug therapy , Silymarin/pharmacology , Animals , Anticarcinogenic Agents/pharmacology , Cell Cycle Proteins/biosynthesis , Cell Line, Tumor , Cell Proliferation , Chemoprevention , Cyclin D1/biosynthesis , Cyclin D1/genetics , Cyclin-Dependent Kinases/biosynthesis , Cyclooxygenase 2/biosynthesis , Drug Combinations , Female , Humans , I-kappa B Proteins/biosynthesis , Interleukin-6/biosynthesis , Lipopolysaccharides , Lung/pathology , Mice , Mice, Inbred A , NF-KappaB Inhibitor alpha , Nitrosamines/adverse effects , Proto-Oncogene Proteins c-akt/biosynthesis , Random Allocation , Retinoblastoma Protein/biosynthesis , STAT3 Transcription Factor/biosynthesis , Silybin , Smoke/adverse effects , Tumor Necrosis Factor-alpha/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...